The interferons: Past, present and future

Digestive and Liver Disease Supplements

Volumn 3, Issue 1, 2009, Pages 3-8

  Meager, A ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

History; Interferon; Properties; Standardisation

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CONSENSUS INTERFERON; GAMMA1B INTERFERON; INTERFERON; INTERFERON BETA SERINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; REIFERON RETARD; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOGENICITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

EID: 66649105754     PISSN: 15945804     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1594-5804(09)60008-5     Document Type: Article

References (14)

1. Isaacs A., and Lindemann J. Virus interference. I. The interferon. Proc R Soc 147 (1957) 258-267
2. Stewart II W.E. The Interferon System (1979), Springer-Verlag, New York
3. Cantell K., and Hirvonen S. Preparation of human leukocyte interferon for clinical use. Tex Rep Biol Med 35 (1977) 138-144
4. Taniguchi T., Mantei N., Schwarzstein M., Nagata S., Muramatsu M., and Weissmann C. Human leukocyte and fibroblast interferons are structurally related. Nature 285 (1980) 547-549
5. De Maeyer E., and De Maeyer-Guignard J. Interferons and Other Regulatory Cytokines (1988), John Wiley & Sons, Chichester and New York
6. Bose S., and Banjeree A.K. Viral defense mechanisms against interferon. In: Meager A. (Ed). The Interferons: Characterization and Application (2006), Wiley-VCH, Weinheim
7. Müller F. Overview of clinical applications of type I interferons. In: Meager A. (Ed). The Interferons: Characterization and Application (2006), Wiley-VCH, Weinheim
8. Nakhaei P., Paz S., and Hiscott J. Activation of interferon gene expression through Toll-like receptor-dependent and -independent pathways. In: Meager A. (Ed). The Interferons: Characterization and Application (2006), Wiley-VCH, Weinheim
9. Harris J.M., Martin N.E., and Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 40 (2001) 539-551
10. Meager A. Measurement of interferon activities. In: Meager A. (Ed). The Interferons: Characterization and Application (2006), Wiley-VCH, Weinheim
11. Meager A., and Gaines Das R. Biological standardization of human interferon beta: establishment of a replacement World Health Organization international biological standard for human glycosylated interferon beta. J Immunol Meth 306 (2005) 1-15
12. Meager A. Development and characterization of spontaneous and therapy-induced antibodies to human interferons. In: Chadha K.C. (Ed). Interferons: Current Status (2007), Research Signpost, Kerala
13. Antonelli G., Bellomi F., Turriziani O., Bagnato F., Scagnolari C., and Dianzani F. In vivo development of antibody to IFNs in IFN-treated patients. In: Chadha K.C. (Ed). Interferons: Current Status (2007), Research Signpost, Kerala
14. Grossberg S.E., and Kawade Y. The development and measurement of antibodies to interferons. In: Meager A. (Ed). The Interferons: Characterization and Application (2006), Wiley-VCH, Weinheim